ONCO/Reveal™
Lung and Colon Cancer Genetic Test

What is Lung and Colon Cancer Genetic Test?

It detects numerous gene regions of interest for researchers looking to explore the genetic sequences of both germline and formalin-fixed paraffin-embedded (FFPE) DNA from lung cancer and colon cancer samples. Utilizing SLIMamp® (stem-loop inhibition mediated amplification) allows researchers to amplify regions of interest in a simple, multiplex reaction for subsequent sequencing on a sequencer using a paired-end read length of 150 (2×150).

The majority of lung cancers (~85%) are classified as non-small cell lung cancer (NSCLC).[4] Nearly half of NSCLC cases are associated with point mutations, or other biomarkers such as EGFR. The prevalence of these biomarkers varies between ethnic populations. The proportion of EGFR mutations is much higher in NSCLC patients in Asia (30-40%) than in NSCLC patients in the US and Europe (10-15%).[1]

non-small cell lung cancer (NSCLC)

85%

35-40% of patients with CRC found activating mutations in KRAS

10-15%

The proportion of EGFR mutations

30-40%

[1] Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2012). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology, 66(2), 79–89. https://doi.org/10.1136/jclinpath-2012-201194

An approximation of 35-40% of patients with CRC found activating mutations in KRAS. Therefore, KRAS-mutation status can be a predictive biomarker for response to anti-EGFR-targeted therapy. There is now strong evidence that cetuximab and panitumumab are effective to patients with CRC whose tumours carry a wild-type KRAS gene. [2]

Patients with CRC found activating mutations in KRAS

35-40%

[1] Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., & McCormack, R. (2012). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology, 66(2), 79–89. https://doi.org/10.1136/jclinpath-2012-201194

Target

Researchers looking to explore the genetic sequences of both germline and formalin-fixed Paraffin-embedded (FFPE) DNA from lung cancer and colon cancer samples.

Table 1. Gene List

AKT1 EGFR FGFR2 NOTCH STK11
ALK ERBB2 FGFR3 NRAS TP53
BRAF ERBB4 KRAS PIK3CA  
CTNNB1 FBXW7 MAP2K1 PTEN  
DDR2 FGFR1 MET SMAD4  
Items
Lung and Colon Cancer Genetic Test
Content
22 genes related to NSCLC and CRC tumour (please refer to table 1 for details)
Sequencing Platform
NGS
Sequencing Type
Amplicon based sequencing
Variants Type
SNVs, indel
Sample Type
FFPE
TAT
7 working days**

Workflow

STEP 01
STEP 01

Pre-sales consultation

STEP 02
STEP 02

Sign the consent form, collect paraffin-embedded sections

STEP 03
STEP 03

Send the specimen to the laboratory

STEP 04
STEP 04

Analyse the experimental data

STEP 05
STEP 05

A total of 7 working days to complete the report**

**Only applicable to the sample that fulfil the QC requirements.

Scroll to Top